COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
DelveInsight’s, “Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight 2023,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Chronic inflammatory demyelinating polyneuropathy Emerging drugs, the Chronic inflammatory demyelinating polyneuropathy pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Chronic inflammatory demyelinating polyneuropathy pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Chronic inflammatory demyelinating polyneuropathy Pipeline Report
To explore more information on the latest breakthroughs in the Chronic inflammatory demyelinating polyneuropathy Pipeline treatment landscape of the report, click here @ Chronic inflammatory demyelinating polyneuropathy Pipeline Outlook
Chronic inflammatory demyelinating polyneuropathy Overview
Chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is an autoimmune-mediated inflammatory disease affecting the peripheral nerves and the nerve roots. This disorder is characterized by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibres) of the peripheral nerves and by immune infiltrates.
For further information, refer to the detailed Chronic inflammatory demyelinating polyneuropathy Unmet Needs, Chronic inflammatory demyelinating polyneuropathy Market Drivers, and Chronic inflammatory demyelinating polyneuropathy Market Barriers, click here for Chronic inflammatory demyelinating polyneuropathy Ongoing Clinical Trial Analysis
Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It contains immunoglobulins collected from human plasma. The drug is infused under the skin into the fatty subcutaneous tissue. The hyaluronidase part of HYQVIA helps more of the Ig get absorbed into the body. The drug is approved for adults with primary immunodeficiency, and in adults, children and adolescents with PI and with secondary immunodeficiency. While it is in Phase III trial for CIDP.
Rozanolixizumab is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to the human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and Immunoglobulin G (IgG), accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG autoantibodies. The drug is under clinical development with the aim of improving the lives of people with pathogenic IgG-autoantibody-driven autoimmune diseases, including ITP, myasthenia gravis (MG), and CIDP, by driving the removal of pathogenic IgG autoantibodies.
Temelimab is a monoclonal antibody designed to neutralize a pathogenic viral envelope protein, encoded by a member of the Human Endogenous Retrovirus-W family, pHERV-W. This protein is thought to be a causal factor in several diseases, including multiple sclerosis, Type 1 diabetes and CIDP. It neutralizes the pHERV-W Env protein without targeting the patient’s immune system, and could be a treatment that is both safe and effective in slowing or stopping the disease’s progress in all its forms. By neutralizing pHERV-W env, GNbAC1 could at the same time block these pathological inflammatory processes and restore remyelination in patients. The drug is currently in Phase I trial for the treatment of CIDP patients.
Chronic inflammatory demyelinating polyneuropathy Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Chronic Inflammatory Demyelinating Polyneuropathy. The companies which have their Chronic Inflammatory Demyelinating Polyneuropathy drug candidates in the most advanced stage, i.e. phase III include, Takeda.
Request a sample and discover the recent advances in Chronic inflammatory demyelinating polyneuropathy Ongoing Clinical Trial Analysis and Medications, click here @ Chronic inflammatory demyelinating polyneuropathy Pipeline Treatment Landscape
Scope of the Chronic inflammatory demyelinating polyneuropathy Pipeline Report
Dive deep into rich insights for drugs for Chronic inflammatory demyelinating polyneuropathy Market Drivers and Chronic inflammatory demyelinating polyneuropathy Market Barriers, click here @ Chronic inflammatory demyelinating polyneuropathy Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Chronic inflammatory demyelinating polyneuropathy Mergers and acquisitions, Chronic inflammatory demyelinating polyneuropathy Licensing Activities @ Chronic inflammatory demyelinating polyneuropathy Emerging Drugs, and Recent Trends
List of Top Selling Market Research Reports in 2023
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com